BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

672 related articles for article (PubMed ID: 36943212)

  • 41. Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm.
    Scheffold A; Stilgenbauer S
    Curr Oncol Rep; 2020 Feb; 22(2):16. PubMed ID: 32025827
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
    Lama TG; Kyung D; O'Brien S
    Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
    Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC
    Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
    Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
    Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
    Patel V; Balakrishnan K; Bibikova E; Ayres M; Keating MJ; Wierda WG; Gandhi V
    Clin Cancer Res; 2017 Jul; 23(14):3734-3743. PubMed ID: 28034907
    [No Abstract]   [Full Text] [Related]  

  • 47. Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.
    Woyach JA; Blachly JS; Rogers KA; Bhat SA; Jianfar M; Lozanski G; Weiss DM; Andersen BL; Gulrajani M; Frigault MM; Hamdy A; Izumi R; Munugalavadla V; Quah C; Wang MH; Byrd JC
    Cancer Discov; 2020 Mar; 10(3):394-405. PubMed ID: 31915195
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
    Cramer P; Fürstenau M; Robrecht S; Giza A; Zhang C; Fink AM; Fischer K; Langerbeins P; Al-Sawaf O; Tausch E; Schneider C; Schetelig J; Dreger P; Böttcher S; Kreuzer KA; Schilhabel A; Ritgen M; Brüggemann M; Kneba M; Stilgenbauer S; Eichhorst B; Hallek M
    Lancet Haematol; 2022 Oct; 9(10):e745-e755. PubMed ID: 35988545
    [TBL] [Abstract][Full Text] [Related]  

  • 49. How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options.
    Yeung CCS; Shadman M
    Curr Oncol Rep; 2019 Jul; 21(8):74. PubMed ID: 31327069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
    Sun C; Nierman P; Kendall EK; Cheung J; Gulrajani M; Herman SEM; Pleyer C; Ahn IE; Stetler-Stevenson M; Yuan CM; Maric I; Gaglione EM; Harris HM; Pittaluga S; Wang MH; Patel P; Farooqui MZH; Izumi R; Hamdy A; Covey T; Wiestner A
    Blood; 2020 Jul; 136(1):93-105. PubMed ID: 32202637
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
    Easaw S; Ezzati S; Coombs CC
    Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):697-704. PubMed ID: 37544810
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia.
    Lipsky AH; Lamanna N
    Cancer; 2023 Jan; 129(1):18-31. PubMed ID: 36326285
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current Perspectives on Therapy for Chronic Lymphocytic Leukemia.
    Awan FT; Al-Sawaf O; Fischer K; Woyach JA
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-10. PubMed ID: 32239979
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy.
    Roeker LE; Thompson M; Mato AR
    Drugs; 2022 Feb; 82(2):133-143. PubMed ID: 34932207
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
    Byrd JC; Wierda WG; Schuh A; Devereux S; Chaves JM; Brown JR; Hillmen P; Martin P; Awan FT; Stephens DM; Ghia P; Barrientos J; Pagel JM; Woyach JA; Burke K; Covey T; Gulrajani M; Hamdy A; Izumi R; Frigault MM; Patel P; Rothbaum W; Wang MH; O'Brien S; Furman RR
    Blood; 2020 Apr; 135(15):1204-1213. PubMed ID: 31876911
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.
    Shirley M
    Target Oncol; 2022 Jan; 17(1):69-84. PubMed ID: 34905129
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
    Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
    Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages.
    Robak P; Robak T
    Expert Opin Biol Ther; 2023 Jan; 23(1):21-35. PubMed ID: 36374125
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.
    Khan Y; O'Brien S
    Future Oncol; 2019 Feb; 15(6):579-589. PubMed ID: 30381956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.